#6 - Dynavax Technologies (NASDAQ:DVAX)
To this point, I’ve focused your attention on what is known as the Big Pharma stocks. In the interest of trying to provide something for every investor, my last two picks are more on the speculative side. The first is Dynavax Technologies (NASDAQ: DVAX). The company discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
That would seem to make the company a participant in the Covid-19 field. And sure enough, Dynavax is partnering with a French company, Valneva, on a Covid-19 vaccine. As the Delta variant and overall vaccine hesitancy are showing, there will be more vaccines developed. While it’s true that Valneva’s supply agreement with the UK was recently terminated, Dynavax says it still has supply contracts valued between $300 to $400 million in 2021.
As of this writing, short interest is over 20% on DVAX stock. But institutional ownership is over 70%. The stock is currently trading near its 52-week high as well as the consensus price target of analysts.
About Dynavax Technologies
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Read More - Current Price
- $11.64
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $25.00 (114.8% Upside)
